Home > Resources > Whitepapers > Why Enterprise CPQ Implementations Fail

Why Enterprise CPQ Implementations Fail

July 23, 2018

You’ve reached a certain point in the evolution of your company and you know it’s time to invest in a CPQ system. But buyer beware: There’s a certain misconception around CPQ systems as being plug-in devices or turnkey-ready overlays of your existing infrastructure, or a simple app you sign up for and that’s it. Yes—the best ones do not require heavy IT resources to get them up and running. But even the best ones require certain things to happen to make their implementation and rollout successful, and most companies, despite the best-laid plans, usually get torpedoed by one of the following issues.

Spotlight

Thimar Al Jazirah

THIMAR AL JAZIRAH CORPORATION (TAC) was founded in 1970’s and was active as a commercial organization in various fields. Responding to the demands of a fast developing healthcare sector in the Kingdom of Saudi Arabia, a new medical & healthcare division was established in the year 1980.

OTHER WHITEPAPERS

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

Preparing Biologics for Commercialization

whitePaper | December 14, 2022

Within the drug development process, there are several steps that occur between the laboratory and final manufacture of the drug product.

COVID-19 Vaccines Production and Analytical Chemistry Solutions

whitePaper | February 2, 2022

Vaccines work by preparing a person’s immune system to recognize and defend itself against a specific disease.

Vendor Partnering in a Bioprocess Manufacturing and Supply Chain Ecosystem

whitePaper | August 30, 2022

Supply constancy, cost, sterility – even a subset of the factors that impact materials selection can be daunting for biopharmaceutical companies embark.

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations